Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 21, 2013

View Archived Issues

New copper-based diagnostic imaging agents for Alzheimer's disease synthesized

Trovagene enters into pharmaceutical collaboration for oncogene mutation detection study

New collaboration to identify biomarkers of Limb-girdle muscular dystrophy 2B

Pharmacokinetics of propofol prodrugs HX-0969w and fospropofol compared

Inhibition of CDK9 explored for CLL at the University of South Australia

Chinese researchers report synthesis of novel DPP IV inhibitors for type 2 diabetes

Multikinase inhibitor DCB-R0237 shows promise in vivo

Novel LSD1 inhibitors display good pharmacological properties

Discovery Labs submits IND for Aerosurf

NNZ-2566 obtains FDA fast track status for fragile X syndrome

Once-daily Striverdi Respimat approved in first E.U. countries

AbbVie details activity of antibody-drug conjugate ABT-414

Health Canada approves Stivarga for gastrointestinal stromal tumors

MGN-1404 trial starts in malignant melanoma

Bayer Intellectual Property patents new NCX1 inhibitors

Piramal Enterprises synthesizes new anticancer agents

Germany's G-BA confirms benefits of Jetrea in vitreomacular traction

Polish researchers design novel CYP1B1 inhibitors for cancer

German researchers disclose novel mGlu5 receptor antagonists

FDA approves Opsumit for PAH

Array BioPharma and Genentech patent new BACE1 inhibitors

FDA approves Cimzia for ankylosing spondylitis, issues complete response letter for axSpA

Meda completes acquisition of Acton Pharmaceuticals

FDA awards orphan drug marketing exclusivity to Ixiaro for pediatric indication

Gene therapy product for spinal muscular atrophy gets fast track designation from FDA

Ariad discontinues EPIC trial of Iclusig in newly diagnosed CML

FDA issues complete response letter for Iluvien

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...